Editorial: rapid disease progression in hepatitis delta-can we turn the tide? Authors' reply

被引：1

作者：

Palom, Adriana ^{[1
]}

Riveiro-Barciela, Mar ^{[1
,2
]}

Buti, Maria ^{[1
,2
]}

机构：

[1] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Dept Internal Med, Liver Unit, Barcelona, Spain

[2] Ctr Invest Biomed Red Enfermedades Hepat & Digest, Barcelona, Spain

来源：

ALIMENTARY PHARMACOLOGY & THERAPEUTICS | 2020年 / 51卷 / 01期

关键词：

D O I：

10.1111/apt.15558

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

LINKED CONTENT This article is linked to Palom et al and Sonneveld and de Knegt papers. To view these articles, visit and .

引用

页码：174 / 175

页数：2

共 22 条

[1] Editorial: rapid disease progression in hepatitis delta-can we turn the tide?
Kayal, Maia
Ungaro, Ryan
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2020, 51 (01) : 172 - 172
[2] Editorial: hepatitis C virus (HCV) disease progression - HCV cure and the elimination of the "ethnic slope". Authors' reply
Le, A. K.
Garcia, G.
Nguyen, M. H.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (10) : 1012 - 1013
[3] Progression of renal disease - can we forget about inhibition of the renin-angiotensin system? Authors' reply
Casas, Juan Pablo
Hingorani, Aroon D.
MacAllister, Raymond J.
Smeeth, Liam
[J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2006, 21 (09) : 2352 - 2353
[4] Editorial: can we afford the new direct-acting anti-virals for treatment of genotype 1 hepatitis C? Authors' reply
Saab, S.
Younossi, Z. M.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (08) : 984 - 985
[5] Editorial: can we get more clinical benefit from thiopurine metabolite testing? Authors' reply
Wong, D. R.
Hooymans, P. M.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 45 (06) : 858 - 859
[6] Editorial: pegylated interferon combined with bulevirtide for chronic hepatitis delta-new life for an old timer? Authors' reply
Jachs, Mathias
Reiberger, Thomas
Ferenci, Peter
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2022, 56 (05) : 914 - 915
[7] Editorial: mesalamine and mucosal microbiome in quiescent ulcerative colitis-what can we learn? Authors' reply
Olaisen, Maya
Fossmark, Reidar
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (12) : 1532 - 1532
[8] Editorial: adherence in coeliac disease - those that can will and those that can't won't (and need support)! authors' reply
Villafuerte-Galvez, J. A.
Mukherjee, R.
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (07) : 935 - 935
[9] Editorial: coeliac disease follow-up guided by gluten immunogenic peptides-are we there yet? Authors' reply
Garzon-Benavides, Marta
Rodriguez-Herrera, Alfonso
Sousa, Carolina
Pizarro-Moreno, Angeles
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2023, 57 (11) : 1341 - 1342
[10] Editorial: microRNAs for the diagnosis of fatty liver disease in the population-are we inching closer towards the target? Authors' reply
Zhang, Xiaofang
Ghanbari, Mohsen
[J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2021, 53 (04) : 559 - 560

← 1 2 3 →